Smoking and Parkinson's disease: A case-control study in Germany

International Journal of Epidemiology

Volumn 26, Issue 2, 1997, Pages 328-339

  Hellenbrand, Wiebke ^a   Seidler, Andreas ^b   Robra, Bernd Peter ^a   Vieregge, Peter ^c   Oertel, Wolfgang H ^d   Joerg, Johannes ^e   Nischan, Peter ^b   Schneider, Eberhard ^f   Ulm, Gudrun ^g  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e Barmen Hospital   (Germany)

^f Asklepios Klinik Harburg   (Germany)

^g Paracelsus Elena Hospital   (Germany)

Author keywords

Case control study; Causation; Epidemiology; Parkinson's disease; Smoking

Indexed keywords

DOPAMINE;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; FEMALE; GENETIC PREDISPOSITION; GERMANY; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK; SMOKING; SMOKING HABIT;

EID: 0030937826     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/26.2.328     Document Type: Article

References (83)

1. Morens D M, Grandinetti A, Reed D, White L R. Cigarette smoking and protection from Parkinson's disease: False association or etiologic clue? Neurology 1995; 45: 1041-51.
2. Riggs J E. The 'protective' influence of cigarette smoking on Alzheimer's and Parkinson's disease. Quagmire or opportunity for neuroepidemiology? Neuroepidemiol 1996; 14: 353-58.
3. Hardy J, Roberts G W. Smoking and neurodegenerative diseases (Letter). Lancet 1993; 342: 1238.
4. Morens D M, Grandinetti A, Reed D, White L R, Ross G W. Smoking-associated protection from Alzheimer's and Parkinson's disease (Letter). Lancet 1994; 343: 356-57.
5. Vieregge P, Heberlein I. Nicotine consumption and Parkinson's disease - does the smoke clear up? (Letter). Mov Disord 1995; 10: 359-60.
6. Seidler A, Hellenbrand W, Robra B P et al. Possible environmental, occupational and other etioiogic factors for Parkinson's disease: A case-control study in Germany. Neurology 1996; 46: 1275-84.
7. Hughes A J, Daniel S E, Kilford L, Lees A. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathologic study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-84.
8. Jessen R J. Statistical Survey Techniques. New York: John Wiley, 1978.
9. Schlesselman J J. Case-Control Studies. Design, Conduct, Analysis. Oxford: Oxford University Press, 1982.
10. Hill A B. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300.
11. Grandinetti A, Morens D M, Reed D et al. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol 1994; 139: 1129-38.
12. Kahn H A. The Dorn study of smoking and mortality among US veterans. Report on eight and one-half years of observation. Natl Canc Inst Monogr 1966; 19: 1-125.
13. Hammond E C. Smoking in relation to the death rates of one million men and women. Natl Canc Inst Monogr 1966; 19: 127-204.
14. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. Br Med J 1976; ii: 1525-36.
15. Rogot E and Murray J L. Smoking and causes of death among U.S. Veterans: 16 years of observation. Public Health Rep 1980; 95: 213-22.
16. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observation on male British doctors. Br Med J 1994; 309: 901-11.
17. Wolf P A, Feldman R G, Saint-Hilaire R G et al. Precursors and natural history of Parkinson's disease: the Framingham study (abstract). Neurology 1991; 41 (Suppl. 1): 371.
18. Nefzger M D, Quadfasel F A, Karl V C. A retrospective study of smoking in Parkinson's disease. Am J Epidemiol 1968; 88: 149-58.
19. Kessler I I, Diamond E L. Epidemiologic studies of Parkinson's disease. I. Smoking and Parkinson's disease: A survey and explanatory hypothesis. Am J Epidemiol 1971; 94: 16-25.
20. Kessler I I. Epidemiologic studies of Parkinson's disease. III. A community-based survey. Am J Epidemiol 1972: 96: 242-54.
21. Baumann R J, Jameson H D, McKean H E, Haack D G, Weisberg L M. Cigarette smoking and Parkinson's disease: 1. A comparison of cases with matched neighbours. Neurology 1980; 30: 839-43.
22. Marttila R J, Rinne U K. Smoking and Parkinson's disease. Acta Neurol Scand 1980; 62: 322-25.
23. Haack D G, Baumann R J, McKean H E, Jameson H D, Turbek J A. Nicotine exposure and Parkinson disease. Am J Epidemiol 1981; 114: 191-200.
24. Godwin-Austen R B, Lee P N, Marmot M G, Stern G M. Smoking and Parkinson's disease. J Neurol Neurosurg Psychiatry 1982; 45: 577-81.
25. Ward C D, Duvoisin R D, Ince S E, Nutt J D, Eldridge R, Calne D B. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983; 33: 815-24.
26. Cazzato G, Capus L, Monti F, Carraro N. Abitudine al fumo e morbo di Parkinson. Riv Neurol (Napoli) 1985; 55: 79-87.
27. Bharucha N E, Stokes L, Schoenberg B S et al. A case-control study of twin pairs discordant for Parkinson's disease: A search for environmental risk factors. Neurology 1986; 36: 284-88.
28. Hofman A, Collette H J A, Bartelds A I M. Incidence and risk factors of Parkinson's disease in the Netherlands. Neuroepidemiol 1989; 8: 296-99.
29. Butterfield P G, Valanis B G, Spencer P S, Lindeman C A, Nutt J G. Environmental antecedents of young-onset Parkinson's disease. Neurology 1993; 43: 1150-58.
30. Jiménez-Jiménez F J, Mateo D, Gimenez-Roldan S. Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson's disease: a case-control-study. Mov Disord 1992; 7: 339-44.
31. Semchuk K M, Love E J, Lee R G. Parkinson's disease: A test of the multifactorial hypothesis. Neurology 1993; 43: 1173-80.
32. Vieregge P, Friedrich H J, Röhl A, Ulm G, Heberlein I. Zur multifaktoriellen Ätiologie der idiopathischen Parkinson-Krankheit. Eine Fall-Kontroll-Studie. Nervenarzt 1994; 65: 390-95.
33. Rajput A H, Offord K P, Beard C M, Kurland L T. A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's Disease. Neurology 1987; 37: 226-32.
34. Sasco A J, Paffenbarger R S. Smoking and Parkinson's disease. Epidemiology 1990; 1: 460-65.
35. Mayeux R, Tang M X, Marder K, Coté L J, Stern Y. Smoking and Parkinson's disease. Mov Disord 1994; 9: 207-12.
36. Mattson M E, Pollack E S, Cullen J W. What are the odds that smoking will kill you? Am J Public Health 1987; 77: 425-31.
37. Ellenberg J. Differential postmorbidity mortality in observational studies of risk factors for neurologic disorders. Neuroepidemiology 1994; 13: 187-94.
38. Hellenbrand W, Seidler A, Boeing H et al. Diet and Parkinson's disease I: A possible role for the past intake of specific foods and food groups - Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 1996; 47: 636-43.
39. Agid Y, Ruberg M, Javoy-Agid F et al. Are dopaminergic neurons selectively vulnerable to Parkinson's disease? Adv Neurol 1993; 60: 148-64.
40. Fearnley J M, Lees J A. Ageing and Parkinson's disease. Brain 1991; 114: 2283-301.
41. Gibb W R G, Lees A T. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson disease. J Neurol Neurosurg Psychiatry 1988: 51: 49-58.
42. Zimmermann T R, Bhatt M, Calne D B. Parkinson's disease in monozygotic twins: a follow-up (Abstract). Neurology 1991; 41 (Suppl. 1): 255.
43. Vieregge P. Genetic factors in the etiology of idiopathic Parkinson's disease. J Neural Transm [P-D Sect] 1994; 8: 1-37.
44. Paulson G W. Addiction of nicotine is due to high intrinsic levels of dopamine. Med Hypoth 1992; 38: 206-07.
45. White N M, Milner P M. The psychobiology of reinforcers. Ann Rev Psychol 1992; 43: 443-71.
46. Wise R A, Rompré P-P. Brain dopamine and reward. Ann Rev Psychol 1989; 40: 191-225.
47. Duvoisin R C, Eldridge R, Williams A, Nutt J, Calne D. Twin study of Parkinson disease. Neurology 1981; 31: 77-80.
48. Poewe W, Gerstenbrand F, Ransmayr G, Plörer. Premorbid personality of Parkinson patients. J Neural Transm Suppl. 1983; 19: 215-24.
49. Todes C J, Lees A J. The premorbid personality of patients with Parkinson's disease. J Neurol Neurosurg Psychiatr 1985; 48: 97-100.
50. Hubble J P, Venkatesh R, Hassanein R E, Gray C, Koller W C. Personality and depression in Parkinson's disease. J Nerv Ment Dis 1993; 181: 657-62.
51. Barbeau A, Cloutier T, Roy M, Plassé L, Paris S, Poirier J. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 1985; ii: 1213-16.
52. Barbeau A, Roy M, Cloutier T, Plassé L, Paris S. Environmental and genetic factors in the etiology of Parkinson's disease. Adv Neurol 1986; 45: 299-306.
53. Smith C A D, Gough A C, Leigh P N et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339: 1375-77.
54. Armstrong M, Daly A K, Cholerton S, Bateman D N, Idle J R. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992; 339: 1017-18.
55. Jiménez-Jiménez F J, Taberno C, Mena M A et al. Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquine. J Neurochem 1991; 57: 81-87.
56. Langston J W, Ballard P, Tetrud J W, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-80.
57. Cholerton S, Arpanahi A, McCracken N et al. Poor metabolisers of nicotine and CYP2D6 polymorphism. Lancet 1994; 343: 62-63.
58. Steventon G, Heafield M T E, Waring R H, Williams A C. Xenobiotic metabolism in Parkinson's disease. Neurology 1989; 39: 883-87.
59. Waring R H, Stevenion G B, Sturman S G, Heafield M T E, Smith M C G, Williams A C. S-methylation in motoneuron disease and Parkinson's disease. Lancet 1989; ii: 356-57.
60. Williams A, Sturman S, Steventon G, Waring R. Metabolic biomarkers of Parkinson's disease. Acta Neurol Scand 1991; 84(Suppl. 136): 19-23.
61. Decina P, Caracci G, Sandik R, Berman W, Mukherjee S, Scapicchio P. Cigarette smoking and neuroleptic-induced parkinsonism. Biol Psychiatry 1990; 28: 502-08.
62. Sandyk R. Cigarette smoking: Effects on cognitive functions and drug-induced parkinsonism in chronic schizophrenia. Int J Neuroscience 1993; 70: 193-97.
63. Janson A M, Moller A. Chronic nicotine treatment counteracts nigral cell loss induced by a partial mesodiencephalic hemitransection: an analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat. Neuroscience 1993; 57: 931-41.
64. Grenhoff J, Janson A M, Svensson T H, Fuxe K. Chronic continuous nicotine treatment causes decreased burst firing of nigral dopamine neurons in rats partially hemitransected at the meso-diencephalic junction. Brain Res 1991; 562: 347-51.
65. Fuxe K, Janson A M, Jansson A, Andersson K, Eneroth P, Agnati L F. Chronic nicotine treatment increases dopamine levels and reduces dopamine utilization in substantia nigra and surviving forebrain dopamine nerve terminal systems after a partial di-mesencephalic hemitransection. Naunyn-Schmiedeberg's Arch Pharmacol 1990; 341: 171-81.
66. Kirch D G, Alho A M, Wyatt R J. Hypothesis: a nicotine-dopamine interaction linking smoking with Parkinson's disease and tardive dyskinesia. Cell Molec Neurobiol 1988; 8: 285-91.
67. Shahi G S, Nagaratnam P D, Moochhala S. 1-methyl-4-phenyl-2,3,6-tetrahydropyridine-induced neurotoxicity: partial protection against striato-nigral dopamine depletion in C57BL/6J mice by cigarette smoke exposure and by b-naphthoflavone-pretreatment. Neurosci Lett 1991; 127: 247-50.
68. Yong V W, Perry T L. Monoamine oxidase B, smoking, and Parkinson's disease. J Neurol Sci 1986; 72: 265-72.
69. Yu P H, Boulton A A. Irreversible inhibition of monoamine oxidase by some components of cigarette smoke. Life Sci 1987; 41: 675-82.
70. Carr L A, Rowell P P. Attenuation of 1-methyl-4-phenyl-2,3,6-tetrahydropyridine-induced neurotoxicity by tobacco smoke. Neuropharmacol 1990; 29: 31 1-14.
71. Oreland L. Monoamine oxidase, dopamine and Parkinson's disease. Acta Neurol Scand 1991: 84 (Suppl. 136): 60-65.
72. Fowler J S, Volkow N D, Wang G-J et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996; 379: 733-36.
73. Götz M E, Künig G, Riederer, Youdim M B H. Oxidative stress: free radical production in neural degeneration. Pharmac Ther 1994; 63: 37-122.
74. Kurth J H, Kurth M C, Poduslo S E, Schwankhaus J D. Association of a monoamine oxidase B allele with Parkinson's disease. Ann Neurol 1993; 33: 368-72.
75. Janson A M, Fuxe K, Sundström E, Agnati L F, Goldstein M. Chronic nicotine treatment partly protects against the 1-methyl-4-phenyl-2,3,6-tetrahydropyridine induced degeneration of nigrostriatal dopamine neurons in the black mouse. Acta Physiol Scand 1988; 132: 589-91.
76. Serschen H, Hashim A, Wiener H L, Lajtha A. Effect of chronic oral nicotine on dopaminergic function in the MPTP-treated mouse. Neurosci Lett 1988; 93: 270-74.
77. Perry T L, Hansen S, Jones K. Exposure to cigarette smoke does not decrease the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neurosci Lett 1987; 74: 217-20.
78. Behmand R A, Harik S I. Nicotine enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. J Neurochem 1992; 58: 776-79.
79. Janson A M, Fuxe K, Goldstein M. Differential effects of acute and chronic nicotine treatment on MPTP (1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine) induced degeneration of nigrostriatal dopamine neurons in the black mouse. Clin Invest 1992; 70: 232-38.
80. Irwin I, Langston J W, DeLanney L E. 4-Phenylpyridine (4PP) and MPTP: The relationship between striatal MPP+ concentrations and neurotoxicity. Life Sci 1987; 40: 731-40.
81. Dwoskin L P, Leibee L L, Jewell J L, Fang Z-X, Crooks P A. Inhibition of (3H)dopamine uptake into rat striatal slices by quaternary n-methylated nicotine metabolites. Life Sci 1992; 50: PL233-PL237.
82. Calne D B, Langston J W. Etiology of Parkinson's disease. Lancet 1983; ii: 1457-59.
83. Hellenbrand W, Boeing H, Robra B-P et al. Diet and Parkinson's disease II: A possible role for the past intake of specific nutrients - Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 1996; 47: 644-50.